Annexon is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibodies and related biologics for inflammatory-related diseases. The company's approach targets complement-mediated inflammatory pathways implicated in neurological and ophthalmological conditions. The organization operates through a pipeline of investigational therapeutics at various development stages rather than generating revenue from marketed products.
The company's lead program, ANX005, is a full-length monoclonal antibody currently in Phase 3 clinical trials for Guillain-Barré syndrome, with completed Phase 2 data in Huntington's disease and ongoing Phase 2a evaluation in amyotrophic lateral sclerosis. ANX007, a Fab fragment, is in Phase 3 development for geographic atrophy. Earlier-stage candidates include ANX1502, an oral small molecule inhibitor in Phase 1 for autoimmune indications, and ANX009, a C1q-blocking Fab in Phase 1 for lupus nephritis.
Annexon was incorporated in Delaware in 2011 and is headquartered in Brisbane, California. The company operates with approximately 99 full-time employees and maintains a market capitalization of approximately $0.8 billion. As a clinical-stage entity, the company does not currently generate product revenues and is primarily focused on advancing its pipeline programs through clinical development.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.01 | $-1.01 | +42.9% | |
| 2023 | $-1.77 | $-1.77 | +31.9% | |
| 2022 | $-2.60 | $-2.60 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |